Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita Inc. (NYSE: DVA) will participate in the BofA Securities 2024 Health Care Conference with its CFO and VP of investor relations engaging in a fireside chat on May 14th, 2024. DaVita is a leading health care provider specializing in kidney care services with a global reach. The company has a strong track record of clinical quality and innovation, serving over 258,600 patients across the U.S. and other countries. DaVita focuses on improving patient outcomes, reducing hospitalizations, and promoting high-quality care standards in the kidney care industry.
DaVita honored 54 nephrology nurses with the DAISY Award for Extraordinary Nurses, recognizing their outstanding patient care during National Nurses Week. The award underscores DaVita's commitment to clinical excellence and compassionate care in kidney disease treatment.
DaVita Inc. announced its financial and operating results for the first quarter of 2024, showcasing significant growth and operational discipline. Consolidated revenues were $3.071 billion, with an operating income of $484 million. Diluted earnings per share stood at $2.65. U.S. dialysis metrics showed stability with a slight decrease in treatments per day. The company repurchased 2.1 million shares of common stock. Despite challenges like closures and delays in claims processing, DaVita Inc. remains focused on delivering clinical excellence and continued innovation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.